GLP-1 Therapy and Ocular Disorders

GLP-1 receptor agonists have revolutionized the treatment of diabetes and obesity, but recent data suggest a potential link to a higher risk of various ocular disorders, especially with long-term use. This episode reviews the findings of these studies, places them in context with the overall benefits of GLP-1s, and covers what pharmacists should know when counseling patients. Listen in to enhance your ability to guide safe, informed medication choices and stay updated on emerging safety information. HOSTJoshua Davis Kinsey, PharmDVP, EducationCEimpactGUESTJamie Pitlick, PharmD, BCPS, BC-ADMProfessor and Chair of Pharmacy PracticeDrake University College of Pharmacy and Health SciencesJoshua Davis Kinsey and Jamie Pitlick have no relevant financial relationships with ineligible companies to disclose.  CPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation:If you are already enrolled in this course, click here to redeem your credit. To purchase this episode and claim your CPE credit, click here. CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe the potential relationship between GLP-1 receptor agonist use and the development of ocular disorders.2. Identify key considerations for pharmacist counseling related to GLP-1 therapy and ocular health.0.05 CEU/0.5 HrUAN: 0107-0000-25-311-H01-PInitial release date: 10/27/2025Expiration date: 10/27/2026Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram